Literature DB >> 20234157

Radiofrequency ablation of liver tumors (I): biological background.

Tomas Vanagas1, Antanas Gulbinas, Juozas Pundzius, Giedrius Barauskas.   

Abstract

Majority of patients suffering from liver tumors are not candidates for surgery. Currently, minimal invasive techniques have become available for local destruction of hepatic tumors. Radiofrequency ablation is based on biological response to tissue hyperthermia. The aim of this article is to review available biological data on tissue destruction mechanisms. Experimental evidence shows that tissue injury following thermal ablation occurs in two distinct phases. The initial phase is direct injury, which is determined by energy applied, tumor biology, and tumor microenvironment. The temperature varies along the ablation zone and this is reflected by different morphological changes in affected tissues. The local hyperthermia alters metabolism, exacerbates tissue hypoxia, and increases thermosensitivity. The second phase - indirect injury - is observed after the cessation of heat stimulus. This phase represents a balance of several promoting and inhibiting mechanisms, such as induction of apoptosis, heat shock proteins, Kupffer cell activation, stimulation of the immune response, release of cytokines, and ischemia-reperfusion injury. A deeper understanding of the underlying mechanisms may possibly lead to refinements in radiofrequency ablation technology, resulting in advanced local tumor control and prolonged overall survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20234157

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  8 in total

Review 1.  Complications after percutaneous ablation of liver tumors: a systematic review.

Authors:  Eylon Lahat; Rony Eshkenazy; Alex Zendel; Barak Bar Zakai; Mayan Maor; Yael Dreznik; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

Review 2.  Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review.

Authors:  Luis Calzadilla Bertot; Masaya Sato; Ryosuke Tateishi; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Eur Radiol       Date:  2011-08-20       Impact factor: 5.315

3.  Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.

Authors:  Hiroto Hatakeyama; Sherry Y Wu; Yasmin A Lyons; Sunila Pradeep; Wanqin Wang; Qian Huang; Karem A Court; Tao Liu; Song Nie; Cristian Rodriguez-Aguayo; Fangrong Shen; Yan Huang; Takeshi Hisamatsu; Takashi Mitamura; Nicholas Jennings; Jeajun Shim; Piotr L Dorniak; Lingegowda S Mangala; Marco Petrillo; Vladislav A Petyuk; Athena A Schepmoes; Anil K Shukla; Madeline Torres-Lugo; Ju-Seog Lee; Karin D Rodland; Anna Fagotti; Gabriel Lopez-Berestein; Chun Li; Anil K Sood
Journal:  Cell Rep       Date:  2016-11-01       Impact factor: 9.423

4.  Role of Pluronic block copolymers in modulation of heat shock protein 70 expression.

Authors:  Reshani H Perera; Tianyi M Krupka; Hanping Wu; Bryan Traughber; David Dremann; Ann-Marie Broome; Agata A Exner
Journal:  Int J Hyperthermia       Date:  2011       Impact factor: 3.914

Review 5.  Tumor ablation: common modalities and general practices.

Authors:  Erica M Knavel; Christopher L Brace
Journal:  Tech Vasc Interv Radiol       Date:  2013-12

6.  Novel use of epidural catheter: Air injection for neuroprotection during radiofrequency ablation of spinal osteoid osteoma.

Authors:  J R Doctor; S L Solanki; V P Patil; J V Divatia
Journal:  Saudi J Anaesth       Date:  2016 Jul-Sep

7.  How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?

Authors:  Yasunori Minami; Haruyuki Takaki; Koichiro Yamakado; Masatoshi Kudo
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.639

8.  The underlying molecular mechanism of intratumoral radiofrequency hyperthermia-enhanced chemotherapy of pancreatic cancer.

Authors:  Liangcai Zhao; Yiming Zhou; Zhibin Bai; Feng Zhang; Xiaoming Yang
Journal:  J Interv Med       Date:  2022-05-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.